“Right now we can’t choose a vaccine,” said the expert. 6:17
(CNN) – China’s leading COVID-19 vaccine developed by Sinovac Biotech was only 50.38% effective in end-stage trials in Brazil. That’s a significantly lower percentage than previous research, according to a statement by the São Paulo government on Tuesday.
Even if the number exceeds the threshold for regulatory approval But it is 78% lower than previously announced, raising questions about the truthfulness of the data and raising doubts about a clear lack of transparency about China’s vaccines.
Analysts said the efficacy rate of Sinovac’s Coronavac vaccine in Brazil, the lowest among global rivals, could undermine international confidence in the Chinese-made vaccine and hinder Beijing’s efforts to repair the image of the deal. Not correct In the early stages of the epidemic, the COVID-19 vaccine was provided to developing countries.
Brazil will have 45 million doses of the Chinese vaccine. 0:53
«The Butantan Institute and the São Paulo government reported that the coronavirus vaccine had an overall effectiveness rate of 50.38% in clinical studies conducted in Brazil. (Efficiency rate) 78% for mild cases and 100% for moderate and severe COVID-19. All rates are above 50 percent set by the WHO (World Health Organization), “the statement said on Tuesday.
The narrow scope for regulatory approvals is likely to raise concern among scientists, since last week the Butantan Institute released some of its ‘clinical efficacy’ effects showing 78% to 100% efficacy in prevention. An infection
Government funds are funding a Phase III vaccine trial involving 13,000 health workers in eight Brazilian states.
“Regarding the overall effectiveness of the analysis, we meet the World Health Organization requirements of 50.38%,” Ricardo Palacios, medical research director at Butantan Biomedical Center in Sao Paulo, said on Tuesday during the meeting. press.
However, on Tuesday, a senior member of the Brazilian Health Ministry told CNN, its subsidiary CNN Brasil, that “effectiveness is within the limit” and because “is at the highest level, we have to wait for ANVISA (Brazil’s health governing body). Evaluate ”.
A Sinovac representative said the company was discussing results. But declined to comment further. The vaccine’s final efficacy rate is set by the Chinese Drug Control Authority, the National Medical Production Administration, according to the agent.